 "Astec Lifesciences rallies over 35% in two trading sessions post Q2 results")
Astec Lifesciences has rallied 16% to Rs 629, extending its Friday’s 20% surge on BSE, after the company reported more than five-fold jump in consolidated net profit at Rs 11.18 crore for the quarter ended September 30, 2016 (Q2FY17). The agrochemicals company had profit of Rs 2.02 crore in the same quarter year ago.
Total income from operations grew 30% at Rs 90 crore during the quarter under review against Rs 69 crore in the corresponding quarter of previous fiscal.
EBITDA (earnings before interest, taxes, depreciation, and amortization) margin improved to 25.9% from 14.77%.
At 06:39 pm, the stock was up 14% at Rs 622 on BSE, as compared to 0.21% rise in the S&P BSE Sensex.
The trading volumes on the counter more than doubled with a combined 334,222 shares changed hands on BSE and NSE so far.
Total income from operations grew 30% at Rs 90 crore during the quarter under review against Rs 69 crore in the corresponding quarter of previous fiscal.
EBITDA (earnings before interest, taxes, depreciation, and amortization) margin improved to 25.9% from 14.77%.
At 06:39 pm, the stock was up 14% at Rs 622 on BSE, as compared to 0.21% rise in the S&P BSE Sensex.
The trading volumes on the counter more than doubled with a combined 334,222 shares changed hands on BSE and NSE so far.
